Brandon Capital

OncoRes Medical develops an imaging technology to provide intraoperative information available to surgeons to assist with the identification of tumor and healthy tissue. OncoRes Medical is an early-stage medical device company located in Perth, Western Australia and is developing the patent-protected technology in collaboration with leading researchers at the University of Western Australia and the Harry Perkins Institute of Medical Research and breast cancer surgeons at the Western Australian public health system. With funding provided by the Medical Research Commercialisation Fund (MRCF), OncoRes Medical aims to develop the technology for use in clinical applications that require the real-time assessment of tissue microstructure.

Ankere is striving to develop transformative therapies based on excellent science that will enable people to live long and healthy lives.

Allay is pioneering a new category of ultra-sustained pain therapeutics to transform post-surgical pain management and recuperation for patients and physicians. Allay’s proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable therapeutics to deliver pain relief within a targeted site over weeks—an order of magnitude greater than the longest-lasting pain treatments currently available. The company’s lead investigational product candidate, ATX101, is currently being evaluated in a Phase 2 clinical study in TKA surgeries. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore.

Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.

Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.

Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.

Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.

Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.

Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. The company's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.

Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. Pathios Therapeutics concentrates on the development of small molecule inhibitors targeting the pH-sensing G protein-coupled receptor GPR65. These inhibitors aim to counteract the immunosuppressive polarization of immune cells, such as tumor-associated macrophages, mediated by GPR65. This polarization is stimulated by the acidic tumor microenvironment commonly found in various cancers.

Denteric is developing a vaccine based on research conducted at the University of Melbourne, with collaborative support from CSL Limited, to fight the disease and will receive the money in three parts each year from 2019 to 2021.

EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.

Allay is pioneering a new category of ultra-sustained pain therapeutics to transform post-surgical pain management and recuperation for patients and physicians. Allay’s proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable therapeutics to deliver pain relief within a targeted site over weeks—an order of magnitude greater than the longest-lasting pain treatments currently available. The company’s lead investigational product candidate, ATX101, is currently being evaluated in a Phase 2 clinical study in TKA surgeries. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore.

Q-Sera technology aims to accelerate the clotting of blood to more rapidly produce high quality serum in blood clotting tubes. Q-Sera Pty Ltd uses the coagulant properties of snake venom-derived proteins to develop blood collection tubes that rapidly produce high quality serum. Australian scientists have found a way to use components of snake venom to improve an essential clinical tool which will assist in optimising laboratory efficiency, clinical diagnosis and patient care. The venom of some snakes (including the Australian Taipan) has a potent ability to coagulate the blood of mammals including humans and it is this ability which caught the interest of a group of Queensland medical scientists and pathologists. The team isolated the potent clotting proteins and used them to develop superior blood collection tubes.

lobal Kinetics Corporation (GKC) was established in 2007 to commercialise innovative technology developed by Professor Malcolm Horne, from the Florey Institute of Neuroscience & Mental Health (the largest Neuroscience research team in Australia and the Southern Hemisphere), and Dr Rob Griffiths, for the precise recording, quantification and reporting of movement symptoms of neurological disease.

Okogen serves the needs of adults and children with ocular infections by developing therapies to reduce suffering, improve quality of life, and preserve vision.The company’s efforts are focused on infectious ocular diseases where treatments are either not available or unsatisfactory.

EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias.

Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.

QUE Oncology, Inc. (QUE) was formed through a collaboration between Emory University, in Atlanta, Georgia, and The University of Queensland (UQ) research commercialization company, UniQuest, in Brisbane, Australia. QUE licenses intellectual property originating from research discoveries at both UQ and Emory’s Institute for Drug Development (EIDD). The leading drug candidate is Q-122, a compound with anti-inflammatory properties that is in Phase 1b clinical development for the treatment of hot flashes in women with breast cancer who are receiving anti-estrogen therapy. Additional cancer research projects that have been identified to supply the QUE Oncology pipeline are designed to address prostate cancer, breast cancer, melanoma, and cancer pain.

Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines. Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterial dissemination to the lungs.

Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen has developed a synthetic version of the elastin protein which is identical to that naturally present in the human body. Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair. Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups. Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.

Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.

MetaBloQ is a privately held biotechnology company focused on developing new drugs to block specific metabolic processes in cancer cells.

Cardiora is a clinical stage biopharmaceutical company that was established in 2015. Cardiora is focussed on developing new treatments for patients with end stage heart failure, which is associated with high mortality rates, recurrent hospital admissions and poor quality of life. Cardiora’s lead program is currently in Phase Ib trials, and IND enabling trials are currently being completed. Cardiora intends to enter Phase II trials in 2017.

lobal Kinetics Corporation (GKC) was established in 2007 to commercialise innovative technology developed by Professor Malcolm Horne, from the Florey Institute of Neuroscience & Mental Health (the largest Neuroscience research team in Australia and the Southern Hemisphere), and Dr Rob Griffiths, for the precise recording, quantification and reporting of movement symptoms of neurological disease.

OccuRx, a Melbourne-based biopharmaceutical company, was established in 2014 with venture funding from the Medical Research Commercialisation Fund, Brandon Capital Partners and Uniseed. The Company’s primary focus is on the development of innovative therapeutic strategies for the treatment of ophthalmic disorders associated with retinal fibrosis.

Solvanix is a biotechnology company that improves stability and reducing the aggregation of fully human antibodies. Traditional monoclonal and fragment antibodies can have limited stability and a tendency to aggregate, which greatly impacts manufacturability, formulation and product quality. Solvanix’ proprietary StAbilize™ technology works by boosting stability and reducing aggregation of monoclonal antibodies, antibody fragments and bi-specifics. The Company is working with its biotech and pharma partners to improve their therapeutic antibodies and is providing licenses to the StAbilize™ technology.

Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”). HCM is a condition in which the heart muscle becomes thick. The thickening makes it harder for blood to leave the heart forcing the heart to work harder to pump blood, leading in many cases to heart failure. Sudden death is caused frequently. There are over 100,000 cases of HCM in the United States alone, often presenting more severely in young adults and athletes; unfortunately the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form. Although various cardiovascular drugs are currently used to treat HCM, there are patients who are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina. Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Protego Medical is a medical technology company that developing a medical device for sternal protection during cardiac surgery.

Auspherix, an Australian early stage anti-infectives company. Auspherix will seek further investment or industry partnerships to move the novel antibiotics into pre-clinical and clinical development, potentially for broad spectrum use.

PolyActiva has developed proprietary drug-polymer conjugate technology that enables site-specific drug delivery from medical device components such as ocular implants, intra-articular gel implants, and drug-eluting fibers.

G I Therapies develops an innovative non-invasive medical device for the treatment of chronic constipation (CC) in adults and children. GI Therapies was established in Melbourne in 2012 to commercialise innovative technology the treat gastrointestinal motility disorders including chronic constipation, irritable bowel syndrome with constipation and gastroparesis.

Q-Sera technology aims to accelerate the clotting of blood to more rapidly produce high quality serum in blood clotting tubes. Q-Sera Pty Ltd uses the coagulant properties of snake venom-derived proteins to develop blood collection tubes that rapidly produce high quality serum. Australian scientists have found a way to use components of snake venom to improve an essential clinical tool which will assist in optimising laboratory efficiency, clinical diagnosis and patient care. The venom of some snakes (including the Australian Taipan) has a potent ability to coagulate the blood of mammals including humans and it is this ability which caught the interest of a group of Queensland medical scientists and pathologists. The team isolated the potent clotting proteins and used them to develop superior blood collection tubes.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Vaxxass is a biotechnology company that develops a novel needle-free vaccination technology. The company uses proprietary dry-coating technology that can eliminate or significantly reduce the need for vaccine refrigeration during storage and transportation - easing the resource and logistics burden of maintaining the vaccine "cold chain". Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.

Signostics produces Biotech medical devices. Their flagship product, Signos, allows healthcare professionals to use ultrasound in their clinical practice. It offers ultrasound platform technology that clinicians can place in their pocket or wear around their neck like a stethoscope. Just as handheld devices transformed the business world, it is anticipated the Signos will change the way healthcare professionals practice medicine. Signostics was established in Adelaide, Australia in 2005 and expanded into the U.S. in 2008, dedicated to developing fast and affordable point‐of‐care medical devices. The company launched its first product into the veterinarian market in January 2009 and gained regulatory approvals to enter the human medical device market for the United States, Europe, and Australia in May 2009. Signostics has offices in Palo Alto, California and Adelaide, South Australia.

Signostics produces Biotech medical devices. Their flagship product, Signos, allows healthcare professionals to use ultrasound in their clinical practice. It offers ultrasound platform technology that clinicians can place in their pocket or wear around their neck like a stethoscope. Just as handheld devices transformed the business world, it is anticipated the Signos will change the way healthcare professionals practice medicine. Signostics was established in Adelaide, Australia in 2005 and expanded into the U.S. in 2008, dedicated to developing fast and affordable point‐of‐care medical devices. The company launched its first product into the veterinarian market in January 2009 and gained regulatory approvals to enter the human medical device market for the United States, Europe, and Australia in May 2009. Signostics has offices in Palo Alto, California and Adelaide, South Australia.

Fibrotech Therapeutics develops and offers novel drug candidates for the treatment of fibrosis in chronic conditions. It develops drugs for kidney diseases, diabetics, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006, Fibrotech Therapeutics is based in Wonga Park, Australia.